Bioequivalence/bioavailability study of a new formulation of imatinib mesylate 100 mg coated tablets versus Glivec® in Brazilian healthy male volunteers in fed state

Bioequivalence/bioavailability study of a new formulation of imatinib mesylate 100 mg coated tablets versus Glivec® in Brazilian healthy male volunteers in fed state

Introduction: Imatinib mesylate is currently the first-line oral treatment for all stages of chronic myeloid leukemia (CML) and is also used in some cases of gastrointestinal stromal tumor (GIST) and acute lymphoblastic leukemia (ALL). Objective: Investigate the bioavailability of two products cont...

Full description

Bibliographic Details
Main Authors: Carlos Eduardo Sverdloff, Vinicius Marcondes Rezende, Paulo Alexandre Rebelo Galvinas, Guilherme Araújo Pinto, Lygia Nerath Bonanato, Fernando Bastos Canton Pacheco
Format: Article
Language:English
Published: Instituto Nacional de Câncer (INCA) 2023-12-01
Series:Revista Brasileira de Cancerologia
Subjects:
imatinib mesylate
therapeutic equivalency
tandem mass spectrometry
tyrosine protein kinase inhibitors
Online Access:https://rbc.inca.gov.br/index.php/revista/article/view/4060

Internet

https://rbc.inca.gov.br/index.php/revista/article/view/4060

Similar Items